FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
------------------------

OMB APPROVAL										
OMB Number:	3235-028									
Estimated average burden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  RICHMAN ERIC I					2. Issuer Name <b>and</b> Ticker or Trading Symbol PHARMATHENE, INC [ PIP ]							(Check	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
ICICITIV	LITT LICE	<u></u>										X	Director			10% Ov	·	
(Last)	Last) (First) (Middle)												Officer (give title below)			Other (s below)	pecify	
C/O PHARMATHENE, INC.,					3. Date of Earliest Transaction (Month/Day/Year) 11/03/2010							President and CEO						
ONE PARK PLACE, SUITE 450					11/05/2010													
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
ANNAPO	OLIS M	ID	21401								X	, ,						
(City)	(5	State)	(Zip)	_	Form filed by More than One Reporting Person										ng Person			
			Table I - Non	-Deriva	ative :	Securit	ies Acqu	uired,	Disp	osed of,	or Benef	ficially O	wned					
Date				2. Transa Date (Month/D		Execut if any	2A. Deemed Execution Date, if any (Month/Day/Year)				s Acquired (A) or f (D) (Instr. 3, 4 and 5		5. Amount of Securities Beneficially Following F Transaction	y Owned (D) or Reported (I) (Ins		Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	(Instr. 3 and				(Instr. 4)	
Common Stock 11/03				11/03/	03/2010		С		7,306	A	\$2.5417	77,879			D			
			Table II - D							sed of, or			ned					
1. Title of	2.	3. Transaction	3A. Deemed	4.	113, 0	5. Numbe		<del>.                                      </del>			7. Title an		8. Price of	9. Numb	er of	10.	11. Nature	
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	n Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transa Code	ction Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		(i) (iiisti. 4		
10% Convertible Note	\$2.5417	11/03/2010		С			\$18,570 <sup>(1)</sup>	(2)		07/28/2011	Common Stock	7,306	(3)	0		D		
Option to	\$3.34	11/03/2010		A		125,000		(	4)	11/03/2020	Common	125,000	(5)	125 (	000	D		

## **Explanation of Responses:**

- 1. The 10% Convertible Note (the "Note") including accrued interest thereon, was convertible into the Issuer's Common Stock at a price of \$2.541667 per share.
- 3. This Note together with a Warrant was received pursuant to a Note and Warrant Purchase Agreement dated as of July 24, 2009, as amended on July 26, 2009 and July 28, 2009, by and among the Issuer and certain noteholders, all as more specifically reported on Form 4 filed with the Securities & Exchange Commission on July 30, 2009.
- 4. The option vests 25% per year beginning on the first anniversary on the date of grant.
- 5. The closing price of the Issuer's common stock on the NYSE Amex on November 3, 2010, the date the option was granted, was \$3.34.

11/05/2010 **fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.